Clinical scenario | Recommendations |
---|---|
Patients with definite APS (+/− SLE) and first venous event | aVK, INR range of 2.0-3.0 |
Patients with definite APS (+/− SLE) and venous recurrent thromboembolism during aVK or arterial thrombosis* | aVK, target INR > 3.0a |
or | |
combination of aspirin (100Â mg daily) and aVK, INR range 2.0-3.0a | |
APS patients (without SLE) with a first non cardioembolic cerebral arterial event, low-risk aPL profile, and reversible predisposing factors | Antiplatelet agents |
SLE patients with venous or arterial thrombosis who do not fulfil APS laboratory classification criteria | Same as patients from the general population who develop venous or arterial thrombosis |